scholarly journals Lipoprotein(a) — A Hallmark in Atherosclerosis and Cardiovascular Diseases

10.5772/61078 ◽  
2015 ◽  
Author(s):  
Indumathi Chennamsetty ◽  
Gert M. Kostner
Keyword(s):  
Cardiovascular Diseases ◽  
Lipoprotein A

Lipoprotein(a) as a unique primary risk factor for early atherosclerotic peripheral arterial disease

2021 ◽  
Vol 14 (6) ◽  
pp. e243231
Author(s):  
John Mayo ◽  
Thomas Hoffman ◽  
Ryan Smith ◽  
Dwight Kellicut
Keyword(s):  
Risk Factor ◽  
Cardiovascular Diseases ◽  
Peripheral Arterial Disease ◽  
Arterial Disease ◽  
Common Condition ◽  
Elevated Plasma ◽  
Early Screening ◽  
Lipoprotein A ◽  
Peripheral Arterial ◽  
Primary Risk Factor

Elevated plasma lipoprotein(a) is a relatively common condition that contributes to many cardiovascular diseases. However, the awareness and testing for this condition remain low. Herein, we present a case of an otherwise healthy and active man who developed symptoms of peripheral arterial disease starting at age 49, and was found to have hyper-lipoprotein(a) as his only notable risk factor. Diagnosis was not made until years later, after an extensive workup. Upon further screening, he was also found to have subclinical coronary and carotid artery atherosclerotic disease. The patient was treated with aspirin, statin, niacin and angioplasty to bilateral superficial femoral arteries with good symptom resolution. Early screening of his son also revealed a similarly elevated lipoprotein(a) level. It is important to raise awareness of this condition and its relationship to early-onset peripheral arterial disease so patients and their families can be appropriately identified, counselled and treated.

The role of lipoprotein (a) in the formation of cardiovascular diseases in childhood

Pharmateca ◽  
2021 ◽  
Vol 9_2021 ◽  
pp. 73-76
Author(s):  
D.I. Sadykova Sadykova ◽  
L.F. Galimova Galimova ◽  
E.S. Slastnikova Slastnikova ◽  
N.E. Usova Usova ◽  
Ch.D. Khaliullina Khaliullina ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Lipoprotein A

The Role of Lipoprotein(a) in Cardiovascular Diseases—Reply

JAMA ◽  
2021 ◽  
Vol 326 (20) ◽  
pp. 2078
Author(s):  
Pradeep Natarajan ◽  
Hannah Miksenas ◽  
James L. Januzzi
Keyword(s):  
Cardiovascular Diseases ◽  
Lipoprotein A

Abstract 13769: Assessing the Risk for Cardiovascular Diseases According to Lipoprotein(a) Levels

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Narek A Tmoyan ◽  
Marat V Ezhov ◽  
Olga I Afanasieva ◽  
Uliana V Chubykina ◽  
Elena A Klesareva ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cardiovascular Diseases ◽  
Carotid Artery ◽  
Lower Extremity ◽  
Carotid Artery Disease ◽  
Lipoprotein A ◽  
Artery Disease ◽  
Lower Extremity Artery Disease

Introduction: There is no common opinion about threshold lipoprotein(a) [Lp(a)] concentration for atherosclerotic cardiovascular diseases (ASCVD) risk. Different clinical guidelines and consensus documents postulated cut-off Lp(a) level as 30 mg/dL or 50 mg/dL. We assessed the concentration of Lp(a) that associated with ASCVD of different locations. Methods: The study included 1224 patients with ASCVD. Lp(a) concentration was measured by enzyme-linked immunosorbent assay in serum. Patients were divided into 3 groups: group I - Lp(a)<30 mg/dL, group II - 30≤Lp(a)<50 mg/dL, group III - Lp(a)≥50 mg/dL (table). Results: Coronary heart disease, carotid artery disease, lower extremity artery disease, myocardial infarction and ischemic stroke were diagnosed in 61%; 34%; 23%; 42% and 11% patients, respectively. Lower extremity artery disease, carotid artery disease and myocardial infarction were more frequent in patients with Lp(a) concentration from 30 to 50 mg/dL compared to patients with Lp(a) <30 mg/dL: 36%, 41%, 48% vs. 17%, 30%, 36% respectively, p<0.01 for all. Subjects with Lp(a) 30-50 mg/dL (n=182, 15%) had a greater odds ratio of lower extremity artery disease, carotid artery disease and myocardial infarction compared to patients with Lp(a) <30 mg/dL (table). ROC analysis demonstrated that Lp(a) cut-off levels for lower extremity artery disease, carotid artery disease, coronary heart disease and myocardial infarction were 26; 21; 37 and 36 mg/dL, respectively. Conclusions: Our results demonstrate that in case of Lp(a) cut-off level of 50 mg/dL about 15% of patients are underestimated for the risk of ASCVD. Lp(a) cut-off level for ASCVD is between 20 and 40 mg/dL regarding the atherosclerosis location.

scholarly journals Lipoprotein(a) and Cardiovascular Diseases　― Revisited ―

2020 ◽  
Vol 84 (6) ◽  
pp. 867-874
Author(s):  
Albert Youngwoo Jang ◽  
Seung Hwan Han ◽  
Il Suk Sohn ◽  
Pyung Chun Oh ◽  
Kwang Kon Koh
Keyword(s):  
Cardiovascular Diseases ◽  
Lipoprotein A

scholarly journals Lipoprotein(a) in Cardiovascular Diseases

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Michele Malaguarnera ◽  
Marco Vacante ◽  
Cristina Russo ◽  
Giulia Malaguarnera ◽  
Tijana Antic ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Smooth Muscle ◽  
Risk Factor ◽  
Cardiovascular Diseases ◽  
Smooth Muscle Cells ◽  
Bypass Graft ◽  
Muscle Cells ◽  
Tissue Type ◽  
Apo B ◽  
Lipoprotein A

Lipoprotein(a) (Lp(a)) is an LDL-like molecule consisting of an apolipoprotein B-100 (apo(B-100)) particle attached by a disulphide bridge to apo(a). Many observations have pointed out that Lp(a) levels may be a risk factor for cardiovascular diseases. Lp(a) inhibits the activation of transforming growth factor (TGF) and contributes to the growth of arterial atherosclerotic lesions by promoting the proliferation of vascular smooth muscle cells and the migration of smooth muscle cells to endothelial cells. Moreover Lp(a) inhibits plasminogen binding to the surfaces of endothelial cells and decreases the activity of fibrin-dependent tissue-type plasminogen activator. Lp(a) may act as a proinflammatory mediator that augments the lesion formation in atherosclerotic plaques. Elevated serum Lp(a) is an independent predictor of coronary artery disease and myocardial infarction. Furthermore, Lp(a) levels should be a marker of restenosis after percutaneous transluminal coronary angioplasty, saphenous vein bypass graft atherosclerosis, and accelerated coronary atherosclerosis of cardiac transplantation. Finally, the possibility that Lp(a) may be a risk factor for ischemic stroke has been assessed in several studies. Recent findings suggest that Lp(a)-lowering therapy might be beneficial in patients with high Lp(a) levels. A future therapeutic approach could include apheresis in high-risk patients in order to reduce major coronary events.

scholarly journals Lipoprotein(a) in an adult sample from the Russian population: distribution and association with atherosclerotic cardiovascular diseases

2021 ◽  
Author(s):  
Marat Ezhov ◽  
Svetlana Shalnova ◽  
Elena Elena B. Yarovaya ◽  
Vladimir Kutsenko ◽  
Svetlana Evstifeeva ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Cardiovascular Diseases ◽  
Population Distribution ◽  
Population Based ◽  
Russian Population ◽  
Lipid Lowering ◽  
Atherosclerotic Cardiovascular Disease ◽  
Lipoprotein A ◽  
Glucose Levels ◽  
Increased Risk

IntroductionLipoprotein(a) (Lp(a)) is recognized as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). The aim of this study was to estimate the distribution of Lp(a) levels in working age adults from the Russian population and to assess its association with ischemic heart disease (IHD), myocardial infarction (MI), stroke, diabetes mellitus (DM), and arterial hypertension (AH).Material and methodsThis substudy of the population-based study “Epidemiology of Cardiovascular Diseases and their Risk Factors in Some Regions of the Russian Federation” (ESSE-RF) included 8461 subjects aged 25–64 years (63.7% women) without lipid-lowering drugs. Atherosclerotic cardiovascular disease was self-reported. Lp(a), apolipoproteins AI and B, and lipid and glucose levels in blood serum were determined.ResultsThe prevalence of Lp(a) ≥ 30 mg/dl was 20.5% and 23.0%, and prevalence of Lp(a) ≥ 50 mg/dl was 13.3% and 15.2%, in men and women, respectively. An association of Lp(a) with IHD, MI, and AH, but not with stroke and DM, was shown. A cut-off level of Lp(a) of 9 mg/dl was determined, above which there was increased frequency of MI (by 59.2%, p = 0.02), IHD (by 33.4%, p < 0.001), and AH (by 11.6%, p < 0.001). In the multivariate analysis only the association of Lp(a) with IHD (1.19 (1.01–1.41), p = 0.038) and MI (1.57 (1.06–2.38), p = 0.028) remained significant.ConclusionsLipoprotein(a) level ≥ 30 mg/dl was detected in every fifth adult aged 25–64 years. Increased risk of MI and IHD starts at an Lp(a) serum level above 9 mg/dl.

Clinical significance and treatment options of increased lipoprotein(a)

2014 ◽  
Vol 155 (16) ◽  
pp. 607-614 ◽  
Author(s):  
Noémi Zsíros ◽  
György Paragh ◽  
Mariann Harangi
Keyword(s):  
Cardiovascular Diseases ◽  
Clinical Significance ◽  
Physiological Function ◽  
Treatment Options ◽  
Physiological Role ◽  
Lipoprotein A

Lipoprotein(a) has been shown to be associated with an increased incidence of cardiovascular diseases for decades. However, only recent research revealed more about its physiological function and its role in the development of cardiovascular diseases. The authors summarize the physiological role of lipoprotein(a), causes and treatment of elevated lipoprotein(a) level, and the association between lipoprotein(a) and cardiovascular diseases. Orv. Hetil., 2014, 155(16), 607–614.

Sign in / Sign up

Export Citation Format

Share Document